LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Strona główna・Stock List・Kura Oncology Inc
Search

Kura Oncology Inc

Closed

SectorHealthcare

8.74 -0.91

Strong Buy

Price update 10 cze 2026, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

8.69

Max

9.1

Key metrics

By Trading Economics

Income

7.7M

-73M

Sales

929K

18M

EPS

-0.828

Profit margin

-401.495

Employees

260

EBITDA

7.4M

-78M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+219.07% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2026

Market Stats

By TradingEconomics

Market Cap

-84M

760M

Previous open

9.65

Previous close

8.74

News Sentiment

By Acuity

100%

0%

315 / 344 Ranking in Healthcare

Kura Oncology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 cze 2026, 23:36 UTC

Earnings

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Read

10 cze 2026, 23:19 UTC

Hot Stocks

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Read

10 cze 2026, 23:09 UTC

Major Market Movers

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Read

10 cze 2026, 23:04 UTC

Earnings

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Read

10 cze 2026, 20:44 UTC

Major Market Movers

Caterpillar Raises Quarterly Dividend 8%

DJ

Read

10 cze 2026, 23:49 UTC

Acquisitions, Mergers, Takeovers

Elliott: Northern Star Should Take No Options Off The Table

DJ

Read

10 cze 2026, 23:48 UTC

Acquisitions, Mergers, Takeovers

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Read

10 cze 2026, 23:48 UTC

Acquisitions, Mergers, Takeovers

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Read

10 cze 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Read

10 cze 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Read

10 cze 2026, 23:46 UTC

Acquisitions, Mergers, Takeovers

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Read

10 cze 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

10 cze 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Read

10 cze 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Read

10 cze 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Read

10 cze 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Read

10 cze 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Read

10 cze 2026, 21:57 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 21:52 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 21:35 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 21:22 UTC

Earnings

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

10 cze 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Read

10 cze 2026, 20:39 UTC

Market Talk
Earnings

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Read

10 cze 2026, 20:34 UTC

Earnings

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Read

10 cze 2026, 20:33 UTC

Earnings

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Read

10 cze 2026, 20:33 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

DJ

Read

10 cze 2026, 20:33 UTC

Market Talk
Earnings

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Read

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

219.07% upside

12 Months Forecast

Average 28.11 USD  219.07%

High 40 USD

Low 15 USD

Based on 10 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Based on 10 analysts giving stock ratings to Kura Oncology Inc - Dist in the past 3 months.

Sentiment

By Acuity

315 / 344 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.

Other stocks from the sector

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat